These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6195379)

  • 1. Skin reactions to vaccinia virus infection in the rabbits immunized with vaccinia-soluble early antigen.
    Yuasa T; Chino F; Tsuruhara T
    Jpn J Med Sci Biol; 1983 Jun; 36(3):147-56. PubMed ID: 6195379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of skin resistance to vaccinia virus in rabbits by vaccinia-soluble early antigens.
    Ueda Y; Tagaya I
    J Exp Med; 1973 Nov; 138(5):1033-43. PubMed ID: 4744920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors concerning the immunity to poxvirus infection.
    Tagaya I; Arita M; Amano H; Ueda Y
    Ann Microbiol (Paris); 1977 Oct; 128(3):409-16. PubMed ID: 203217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response in rabbits to surface components of extracellular and intracellular forms of vaccinia virus.
    Balachandran N; Seth P; Mohapatra LN
    Infect Immun; 1980 Sep; 29(3):846-52. PubMed ID: 7000705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of vaccinia virus replication in skin of tuberculin-sensitized animals challenged with PPD.
    Lodmell DL; Ewalt LC; Notkins AL
    J Immunol; 1976 Nov; 117(5 Pt.2):1757-61. PubMed ID: 62789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed hypersensitivity in vaccinia-infected mice. II. Resistance of peritoneal macrophages against vaccinia infection.
    Ueda S; Nozima T
    Acta Virol; 1973 Jan; 17(1):41-9. PubMed ID: 4405395
    [No Abstract]   [Full Text] [Related]  

  • 7. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immunity to herpes simplex virus mediated by interferon.
    Lodmell DL; Notkins AL
    J Exp Med; 1974 Sep; 140(3):764-78. PubMed ID: 4369835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble antigens of vaccinia virus. Note I. Chemical and biological properties. Immunogenic capacity.
    Mihăilescu R; Olinescu A; Popa L; Stavri H; Iancu L
    Arch Roum Pathol Exp Microbiol; 1987; 46(1):35-46. PubMed ID: 2449147
    [No Abstract]   [Full Text] [Related]  

  • 10. The immune response to vaccinia virus infection in mice: analysis of the role of antibody.
    Novembre FJ; Raska K; Holowczak JA
    Arch Virol; 1989; 107(3-4):273-89. PubMed ID: 2684096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune response to infection with vaccinia virus in mice. I. Infection and the production of antibody neutralizing cell-associated and cell-free virus.
    Hutt LM
    J Hyg (Lond); 1975 Jun; 74(3):301-14. PubMed ID: 168248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of humoral immunity and induction of proliferating T lymphocytes in vaccinia virus-infected rabbits and rhesus macaques.
    Schäffner JW; Dittmer U; Otteken A; Coulibaly C; Bodemer W; Voss G; Hunsmann G
    Am J Vet Res; 1994 Sep; 55(9):1250-5. PubMed ID: 7802392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus.
    Rosenberg GL; Farber PA; Notkins AL
    Proc Natl Acad Sci U S A; 1972 Mar; 69(3):756-60. PubMed ID: 4335071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of recovery from systemic vaccinia virus infection. I. The effects of cyclophosphamide.
    Worthington M; Rabson AS; Baron S
    J Exp Med; 1972 Aug; 136(2):277-90. PubMed ID: 5043413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the immune response elicited by the vaccinia virus L3 protein delivered as naked DNA.
    Ramírez M; Santos S; Martínez O; Rodríguez R; Miranda E; Ramos-Perez WD; Otero M
    Vaccine; 2018 Apr; 36(15):2049-2055. PubMed ID: 29525282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens.
    Lobato ZI; Coupar BE; Gray CP; Lunt R; Andrew ME
    Vet Immunol Immunopathol; 1997 Nov; 59(3-4):293-309. PubMed ID: 9477479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of vaccinia antigen and antibody by counterelectrophoresis.
    Kyriakidou A; Kourea-Kremastinou T; Papaevangelou G; Vassiliadis P
    Pathol Microbiol (Basel); 1973; 39(2):126-34. PubMed ID: 4196961
    [No Abstract]   [Full Text] [Related]  

  • 19. Macrophage immunity to vaccina virus: factors affecting macrophage immunity in vitro.
    Schultz RM; Woan MC; Tompkins WA
    J Reticuloendothel Soc; 1974 Jul; 16(1):37-47. PubMed ID: 4137839
    [No Abstract]   [Full Text] [Related]  

  • 20. Target antigen of vaccinia-infected cells recognized by virus-specific cytotoxic T lymphocytes.
    Oie M; Ichihashi Y
    Microbiol Immunol; 1981; 25(4):361-75. PubMed ID: 6973058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.